Introduction

CD8
+ T cells (T CD8+ ) play a major role in the elimination of viruses, intracellular pathogens, and tumours. Antigenspecific T CD8+ recognize peptides of 8-11 amino acids bound to major histocompatibility class I (MHC-I) molecules. Activation of naïve T CD8+ to become effector T CD8+ requires that antigenic peptides be presented on MHC-I by professional antigen-presenting cells (pAPCs), in particular dendritic cells (DCs). Antigenic peptides can be generated in pAPCs by two spatially distinct routes. Direct presentation occurs when peptides are generated from endogenous antigen synthesized within the pAPC. Thus, direct presentation allows the sampling of the contents of a cell and clearance of infected cells by effector T CD8+ . Alternatively, cross presentation involves the uptake by pAPCs of exogenously synthesized antigen derived from donor cells or pathogens. The endocytosed antigen is then processed and presented by the pAPC. 1 The cross presentation pathway allows the generation of effector T CD8+ when antigen is expressed only within certain cell types (such as tumours of non-lymphoid origin or pathogens that do not infect pAPCs), or when a pathogen has evolved to block the direct presentation pathway in infected pAPCs.
Summary
CD8
+ T cells (T CD8+ ) differentiate into effector cells following recognition of specific peptide-major histocompatibility complex (MHC) class I complexes (pMHC-I) on the surface of professional APCs (pAPCs), such as dendritic cells. Antigenic pMHC-I can be generated from two spatially distinct sources. The direct presentation pathway involves generation of peptide from protein substrate synthesized within the cell that is presenting the pMHC-I. Alternatively, the cross presentation pathway involves presentation of antigen that is not synthesized within the presenting cell, but is derived from exogenous proteins synthesized within other donor cells. The mechanisms by which cross presentation of exogenous antigens occur in vivo remain controversial. The C-type lectin scavenger receptor A (SR-A) has been implicated in a number of potential cross presentation pathways, including the presentation of peptide bound to heat shock proteins, such as glycoprotein 96 (gp96), and the transfer of pMHC-I from a donor cell to the pAPC. We demonstrate here that initiation of T CD8+ responses is normal in mice lacking SR-A, and that the redundancy of ligand binding exhibited by the SR family is likely to be an important mechanism that ensures cross presentation in vivo. These observations emphasize the requirement to target multiple receptors and antigen-processing pathways during the rational design of vaccines aimed at eliciting protective T CD8+ .
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The cellular and molecular mechanisms by which cross presentation occurs have been widely studied in vitro, but remain controversial in vivo. A number of studies indicate that the primary substrates for cross presentation in vivo are stable long-lived proteins. [2] [3] [4] [5] However, other studies of cross presentation in vivo implicate the transfer of antigenic peptides that are bound to molecular chaperones. [6] [7] [8] [9] Alternatively, minimal antigenic peptide may be transferred between cells in vitro via the relocation of peptide-MHC complexes from a donor cell to a pAPC. 10, 11 The C-type lectin family scavenger receptor A (SR-A) has been implicated in both the internalization of molecular chaperones 5, 12 and the transfer of peptide-MHC complexes between cells. 11,13 SR-As are trimeric transmembrane glycoproteins [14] [15] [16] that bind and mediate the internalization of modified low-density lipoprotein (LDL) 17, 18 and have been implicated in the development of atherosclerosis. 19, 20 SR-As are expressed by macrophages and DCs, 13, 21 the cells that are generally held to be responsible for mediating cross priming in vivo. SR-A has been implicated as having a role in the initiation of immune responses by binding, internalizing, and trafficking inflammatory microbial products such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) 22, 23 and as a phagocytic receptor for the internalization of particulates and microbes. 22, [24] [25] [26] [27] Additionally, targeting of antigen to SR-A dramatically enhances cross presentation in vitro.
28
Based on data implicating SR-A in the cross priming process, we sought to establish the requirement for SR-A in the induction of antiviral T CD8+ responses and the initiation of T CD8+ responses following immunization with molecular chaperone-peptide complexes. We find that, in contrast to in vitro studies, blocking of SR-A function in vivo affects neither the initiation of antiviral T CD8+ responses nor the cross priming of T CD8+ with cellular antigen or molecular chaperone-peptide complexes. However, blocking of the binding of all scavenger receptors with a competitive inhibitor significantly reduces the ability of DCs pulsed with molecular chaperone-peptide complexes to induce antigen-specific T CD8+ , indicating that the redundancy in scavenger receptor ligands can compensate for a lack of SR-A. The presence of a number of redundant receptors reduces the ability of pathogens to specifically block the cross presentation pathway in vivo, indicating the importance of this pathway for induction of protective T CD8+ .
Materials and methods
Animals
Female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA) or the National Cancer
Institute (Frederick, MD). SR-A null (SR-A )/)
) mice were a generous gift from M. W. Freeman (Massachusetts General Hospital, Boston, MA). 29 OT-1 T-cell receptor (TCR) recombinase activation gene 1 )/) (RAG1 )/) ) transgenic mice 30, 31 and F5 RAG1 )/) mice 32 were obtained from the National Institute of Allergy and Infectious Diseases Exchange Program. B6.SJL-Ptprca/BoAiTac mice were purchased from Taconic Farms (Germantown, NY) and bred to both OT-1 TCR and F5 TCR mice to produce OT-1.SJL and F5.SJL offspring, respectively. All mice were maintained under specific pathogen-free conditions at the M. S. Hershey Medical Center, and all studies were approved by the Penn State College of Medicine Institutional Animal Care and Use Committee.
Viruses
Vaccinia virus (VACV) and adenovirus (Ad) were a kind gift from Dr Jon Yewdell and Dr Jack Bennink (Laboratory of Viral Diseases, NIAID, Bethesda, MD). Influenza virus A/PR8 was obtained from SPAFAS Pathogen Free Egg Facility (Voluntown, CT).
Cell lines and cultures
All media and supplements were purchased from Invitrogen (Carlsbad, CA) except where noted. b 2 -microglobulin (b 2 m) )/) fibroblasts 33 were maintained in Dulbecco's modified Eagle's minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS) supplemented with penicillin/streptomycin and 2 mM L-glutamine. DCs and macrophages were grown from bone marrow as previously described. 34 
Proteins
Calreticulin (CRT) was purified and depleted of endotoxin as previously described; 36, 37 endotoxin levels were assessed with the Cambrex (Walkersville, MD) QCL-1000 LAL assay. CRT was labelled with AlexaFluor 647-succinimidyl ester (Invitrogen), and labelled protein was sub-sequently isolated from unincorporated fluor by size exclusion chromatography. 12, 36, 38 OVA20 peptide 39 (contains SIINFEKL) was cross-linked to CRT using N-succinimidyl 3-(2-pyridyldithio)-propionate (Pierce, Rockford, IL) as previously described. 8 CRT/OVA20 complexes were separated from free peptide by dialysis and size exclusion chromatography.
The N-terminal domain (NTD) of glycoprotein 96 (gp96; amino acid residues 22-337), in pET15b, was expressed in Escherichia coli strain BL21 cells and purified by nickel agarose affinity chromatography. Endotoxin was depleted from the affinity column-bound gp96 by washing with 100 column volumes of 1% Triton X-114 in phosphate-buffered saline (PBS) and subsequently with three column volumes of PBS. Endotoxin-depleted gp96 was eluted in 150 mM imidazole and dialysed against sterile PBS, and endotoxin levels were assessed as above. Where indicated, gp96-AlexaFluor conjugates were prepared according to the manufacturer's instructions (Molecular Probes, Eugene, OR). Succinimidyl ester conjugates were used in all studies and unconjugated dye was removed by size exclusion chromatography (Sephadex G-25). Final dye coupling ratios varied from 1Á5 to 2Á5 mol dye:mol protein.
gp96 NTD-peptide complexes were prepared as follows. Peptide (OVA 257-264 or influenza NT60 NP 366-374 ) was incubated with gp96 (1 mg/ml) at 40°for 3 hr. Under these conditions, the gp96 undergoes a tertiary conformational change and is receptive to peptide association. Unbound peptide was subsequently removed by five cycles of centrifugal ultrafiltration, using a 10 000 MWCO VIVASPIN 2 column (Sartorius, Edgewood, NY) according to the manufacturer's instructions.
Immunizations
C57BL/6 mice were immunized intraperitoneally with 1 mg of OVA 257-264 peptide, 10 lg of LPS (both from Sigma, St Louis, MO) and 100 lg of FGK45 anti-CD40 antibody (from Dr R. Noelle, Dartmouth College, Lebanon, NH). CRT/OVA20 was injected into mice intraperitoneally along with either 10 lg of LPS or 100 lg of poly I:C (Sigma). Mice were immunized intradermally with amounts of gp96-OVA 257-264 or gp96-NP 366-374 indicated.
For influenza infections, mice were immunized with approx 600 haemagglutination units of A/Puerto Rico/8/ 34 virus intraperitoneally. For VACV infections, mice were immunized with 10 7 plaque-forming units (PFU) intravenously. To study cross priming, mice were immunized intraperitoneally with b 2 m )/) cells that were electroporated with antigen as described below or immunized intradermally in the ear pinnae with 10 6 PFU of the adenovirus rAdCMVNP, rAdK14NP or rAdSPCNP.
For cellular bone marrow-derived DC (BMDC) immunization, BMDCs were incubated with anti-CD11c beads and sorted using an AutoMACS magnetic sorter (Miltenyi Biotech, Auburn, CA). Where indicated, BMDCs were incubated with 75 lg/ml fucoidin (Sigma) to block SR-A binding and then with either gp96-OVA 257-264 or gp96-NT60 NP 366-374 at 4 or 37°. BMDCs were washed extensively to remove any free gp96 and injected intravenously into recipient mice.
Electroporation
Electroporation was performed as previously described. 40 Briefly, approximately 4 · 10 6 b 2 m )/) cells were suspended in PBS containing 1 mg/ml OVA with 10 mM MgCl 2 and incubated on ice for 10 min. The cells were then electroporated in disposable cuvettes (Bio-Rad, Hercules, CA) on a Bio-Rad gene pulser at 0Á25 kV with a capacitance of 250 lF. Following electroporation, cells were incubated on ice for an additional 10 min and washed three times with 10% Iscove's modified Dulbecco's medium (IMDM). Cells were irradiated at 20 000 rad prior to injection.
Adoptive transfer of T-cell receptor (TCR) transgenic cells
Spleens and lymph nodes were removed and homogenized to produce a single cell suspension, and mononuclear cells isolated either by centrifugation over a lymphocyte separation medium (LSM) cushion or by suspension in ACK lysing buffer (both from Cambrex) for 5 min. For in vivo killing (IVK) assays, cells were pulsed with 1 lg of OVA 257-264 peptide, influenza NT60 NP 366-374 peptide, or no peptide. Cells were washed twice and labelled with 0Á5 lM (NP 366-374 peptide pulsed) or 5 lM (OVA 257-264 peptide pulsed) 5-(and 6-)carboxyfluorescein diacetate-succinimidyl ester (CFDA-SE) (Molecular Probes) for 10 min at 37°. Each recipient received 2 · 10 6 cells pulsed with each peptide intravenously or retro-orbitally 4 or 7 days post immunization. Effector function in IVK assays was measured as the percentage of targets killed by calculating the ratio of antigen-unpulsed, low-CFDA-SE cells to pulsed, high-CFDA-SE labelled cells. For proliferative studies, cells were washed twice, labelled with CFDA-SE, and washed once prior to intravenous injection.
T-cell culture
Cervical lymph nodes and the spleen were removed 30 days post immunization and homogenized, and red blood cells lysed using ACK lysing buffer. Splenocytes (3 · 10 7 ) were stimulated with 1/20-1/25 the number of PR8 NP 366-374 peptide-pulsed APCs, in RPMI-1640 medium containing 10% FBS supplemented with penicillin/ streptomycin, 2 mM L-glutamine, non-essential amino acids, sodium pyruvate, and 2-mercaptoethanol, and incubated at 37°for 6 days.
Cytokine production
Mononuclear cells isolated from splenocytes harvested 5 or 7 days post-immunization or plated T CD8+ that were harvested were washed twice after isolation over an LSM cushion as described above and plated in triplicate into individual wells of a 96-well plate (3 · 10 6 cells per well) for an intracellular cytokine secretion assay. Cells were stimulated with 1 lg of the relevant peptides for 2 hr at 37°. Brefeldin A (BFA; Sigma) at 10 lg/ml was added 2 hr after stimulation with peptide and cells were incubated for a further 4 hr. T CD8+ were then assayed for production of interferon (IFN)-c by flow cytometry. An enzyme-linked immunosorbent assay (ELISA) was performed for the release of IFN-c in the medium as per the manufacturer's instructions (Biosource International, Camarillo, CA).
Flow cytometry
For all assays, cells were incubated on ice with Fc Block and 20% mouse serum (Sigma) for 20 min prior to staining for 40 min with the appropriate antibody. For cytokine production analysis, all antibodies were purchased from BD Biosciences (San Jose, CA) except where noted. Cells were stained with anti-CD8 phycoerythrin (PE)-Cy5 antibody (Clone 53-6Á7), washed once with PBS, and fixed with 1% paraformaldehyde (PFA). Fixed cells were then stained with anti-IFN-cfluorescein isothiocyanate (FITC) antibody (Clone XMG1.2) in 0Á5% saponin, washed, and analysed. For adoptive transfer and IVK readouts, anti-CD45.1-PE antibody (Clone A20; EBioscience, San Diego, CA) was used to identify OT-1.SJL, F5.SJL and B6.SJL cells. For SR-A expression by macrophages, anti-CD11b-allophycocyanin (APC) antibody (Clone M1/70) and anti-CD204-FITC antibody (Clone 2F8) (Serotec, Raleigh, NC) were used. For gp96 and CRT binding to BMDCs, anti-CD11c-PE antibody (Clone N418; EBioscience) was used.
Fluorescent staining and microscopy
To measure binding of gp96, wild-type or SR-A )/)
BMDCs were plated on eight-well glass chamber slides (Nalge Nunc International, Rochester, NY). Uptake of gp96 was visualized following incubation of BMDCs with 25 lg/ml gp96-AlexaFluor 647 for 30 min at 4°. Following fixation with 4% PFA, BMDCs were stained with anti-CD11c-PE antibody (Clone N418) and slides were then overlaid with ProLong Gold antifade reagent (Molecular Probes).
Data analysis
For statistical analysis, the t-value of sample sets was determined using the unpaired Student's t-test. The t-value and degrees of freedom from each sample set were then used to calculate P-values such that P-values less than 0Á05 were considered to be statistically significant while those greater than 0Á05 were considered to be not significant.
Results
Mice lacking SR-A mount normal T CD8+ responses following peptide immunization
To examine the requirement for SR-A in the induction of T CD8+ responses, we obtained mice with a genetically targeted mutation of SR-A. To ensure that SR-A )/) mice lacked cell surface expression of the receptor, we generated bone marrow-derived macrophages and analysed expression by flow cytometry. As expected, SR-A )/) mice lacked detectable SR-A expression (Fig. 1a-c) . However, equivalent levels of cell surface MHC class I were expressed by wild-type and SR-A )/) DCs (Fig. 1d ).
To examine whether SR-A )/)
mice displayed an impaired ability to mount a T CD8+ response, we immunized with OVA 257-264 peptide, an immunization strategy that does not require antigen processing and so should not be affected by a lack of SR-A. Equivalent levels of IFN-c were produced in response to OVA 257-264 peptide after immunization of SR-A )/) and wild-type mice (Fig. 1e) .
SR-A
)/) mice develop normal primary and memory T CD8+ responses to viral challenge in vivo SR-A )/) mice are more susceptible to bacterial infections than wild-type mice. 29, 41 To examine antiviral T CD8+ responses, we immunized SR-A )/) or wild-type mice with either recombinant VACV expressing OVA (rVACV-OVA; Fig. 2a,c) or influenza virus A/PR8 virus (Fig. 2b,d ). We then examined the production of IFN-c in response to incubation with antigenic peptide in either the primary (day 7; Fig. 2a,b) or memory (day 30; Fig. 2c,d ) response. No significant differences were found in the number of IFN-c-producing T CD8+ between SR-A )/) mice and wild-type mice in both the primary and memory T CD8+ responses, indicating that SR-A )/) mice are able to mount both normal primary and memory T CD8+ responses upon challenge with VACV and influenza. In addition, no obvious signs of distress, increased morbidity or mortality were observed in SR-A )/) mice challenged with either VACV or influenza when compared with wild-type mice. and wild-type mice (Fig. 3a-c) .
Although immunization with presentation-incompetent cells restricts presentation to the cross priming pathway, this strategy may not closely mimic mechanisms of cross priming used in vivo. In particular, the introduction of b 2 m )/) cells may not allow the transfer of antigen via gap junctions 42 and the lack of stable cell surface MHC class I may prevent the transfer of peptide-MHC complexes via 'nibbling'. 10, 11 To more closely examine these possibilities, SR-A )/) and wild-type mice were immunized with replication-deficient adenovirus expressing influenza NP driven by the tissue-targeted keratin 14 (K14; keratinocyte) or surfactant protein C (SPC; type II pneumocyte) promoters, or by the ubiquitous cytomegalovirus (CMV) promoter. We have previously demonstrated that intradermal immunization with K14 promoter-driven antigen results exclusively in induction of NP-specific T CD8+ via the cross presentation pathway. 43 We monitored the proliferation of adoptively transferred NP-specific F5.SJL T CD8+ following immunization. As expected, intradermal infection with adenovirus expressing NP driven by the SPC lung promoter did not trigger T CD8+ proliferation (Fig. 3f) , as virus did not reach the lung following immunization via this route. However, immunization with virus expressing antigen driven by the ubiquitous CMV promoter (Fig. 3d and data not shown) or the targeted K14 promoter (Fig. 3e,g ) stimulated F5 proliferation in both wild-type (Fig. 3d,e) and SR-A )/) (Fig. 3g) mice. To ensure that proliferating T CD8+ differentiated into effector cells, we re-stimulated splenocytes from wild-type or SR-A )/) mice immunized with adenovirus as above with NP 366-374 peptide. Seven days later, the proportion (Fig. 3h ) and absolute number (Fig. 3i ) of T CD8+ producing IFN-c in response to NP 366-374 peptide was measured. As expected, ubiquitously expressed antigen stimulated robust effector function while lung promoter-driven antigen failed to stimulate effector cell function following intradermal immunization. However, there was no difference in the abilities of wild-type and SR-A )/) mice to mount an NP 366-374 -specific effector T CD8+ response following immunization with adenovirus expressing K14 promoter-driven antigen. Thus, no detectable difference was observed in the abilities of wild-type and SR-A
mice to cross-present virus-encoded antigen.
SR-A )/) mice mount normal responses following immunization with chaperone-peptide complexes
We measured the binding of molecular chaperones gp96 (Fig. 4a,b) and calreticulin (CRT) (Fig. 4c) by BMDCs. Binding was measured at 4°to prevent any contribution of fluid phase uptake to the signal measured by flow cytometry. 41, 44 Binding and internalization of fluorescently labelled gp96 was also visualized by deconvolution microscopy (Fig. 4d,e BMDCs, suggesting the presence of an additional chaperone receptor on these cells. To address this issue, BMDCs were incubated in the presence or absence of fucoidin, a competitive ligand for members of the scavenger receptor family. We have previously demonstrated that addition of fucoidin inhibits gp96 binding to pAPCs in vitro when measured by flow cytometry. 12 The addition of fucoidin inhibited gp96 binding and internalization measured by confocal microscopy to background levels (Fig 4e) , indicating a role for other scavenger receptors in the uptake of molecular chaperones in vitro.
To examine the role of SR-A in the priming of T CD8+ by molecular chaperones, we adoptively transferred CFDA-SE-labelled OT-1.SJL (Fig. 5a-j ( Fig. 5f-j, Fig. S1d-f ) or wild-type mice (Fig. 5a- To assess the effector function of T CD8+ triggered by chaperone-peptide complexes, we examined their ability to clear peptide-pulsed targets in vivo. We immunized SR-A )/) or wild-type mice with titrated amounts of CRT complexed to an OVA 20-mer peptide containing OVA 257-264 (CRT-OVA20) in the presence of LPS (Fig. 5k ) or poly I:C (Fig. 5l) . Alternatively, SR-A )/) or wild-type mice were immunized with gp96 coupled to OVA [257] [258] [259] [260] [261] [262] [263] [264] (Fig. 5m ) and the function of adoptively transferred OT-1 examined. Four days (Fig. 5k ,l) or 7 days (Fig. 5m) post immunization, the antigen-specific cytolytic activity was compared with activity against cells pulsed with an irrelevant peptide. No difference in killing was found between SR-A )/) and wild-type mice when immunized with either CRT/OVA20 or gp96 coupled to OVA 257-264 .
Scavenger receptor blockade prevents induction of T CD8+ by gp96-peptide complexes
To further dissect the role of receptor-mediated endocytosis in the induction of T CD8+ by chaperone-peptide complexes, we immunized wild-type mice with either wild-type ( Fig. 6a-d) or SR-A )/) ( Fig. 6e-h ) BMDCs pulsed with gp96 coupled to OVA 257-264 . Exposure to gp96 was at 37° (Fig. 6a,b ,e,f) or 4° (Fig. 6c,d,g,h) , a temperature at which internalization will not occur. The proliferation of adoptively transferred OT-1.SJL T CD8+ was measured 96 hr post immunization. As expected, there was no OT-1.SJL T CD8+ proliferation when BMDCs were pulsed with gp96 without peptide (Fig. 6a,c,e,g ). However, proliferation of OT-1.SJL T CD8+ was equivalent in recipient mice immunized with SR-A )/) ( Fig. 6e-h ) or wild-type BMDCs (Fig. 6a-d ) and when BMDCs were pulsed with gp96 at 37° (Fig. 6b,f) or 4° (Fig. 6d,h ). To examine whether other scavenger receptors are involved in internalization of gp96-peptide complexes during initiation of T CD8+ responses, we pulsed SR-A )/) or wild-type BMDCs with gp96-OVA 257-264 complexes at 4°in the presence or absence of fucoidin and immunized wild-type mice. Effector cytolytic activity displayed against OVA 257-264 peptide-pulsed targets was compared to cytolysis of targets pulsed with an irrelevant peptide. Immunization with wild-type BMDCs elicited slightly higher levels of antigen-specific cytolysis than SR-A )/) BMDCs, but addition of fucoidin during the gp96 pulse reduced killing by approximately 50% with either population of BMDCs (Fig. 6i) .
Discussion
SR-A has been repeatedly implicated as a receptor that plays a role in the priming of T CD8+ specific for exogenous antigens via a variety of mechanisms. Here we have utilized mice that are genetically deficient for SR-A to dissect the role of this receptor in the cross priming process. Our data demonstrate conclusively that SR-A is not required for the initiation of T CD8+ responses following viral challenge to antigen exclusively targeted to the cross priming pathway or following immunization with peptide-chaperone complexes. The implication is that cross presentation is an evolutionarily important means of generating protective T CD8+ that is protected by significant mechanistic redundancy. The lack of a definitive, indispensable role for SR-A in vivo could be explained by a number of possibilities. The majority of investigations on the role of SR-A in cross presentation have been conducted in vitro and have used competitive inhibitors to examine the requirement for the receptor. In vitro studies have implicated many cell types and mechanisms in the cross priming pathway, but in vivo data substantiating the role of these cells and pathways are lacking. An example is the SR-A-dependent transfer of peptide-MHC complexes from one cell to another. A number of studies 10, 11, 45 have described the transfer of peptide-MHC complexes between cells, particularly DCs, in vitro. However, studies examining the requirement for bone marrow-derived APCs during cross priming have utilized chimeric mice with MHCmismatched or presentation-incompetent APCs. [46] [47] [48] The published data indicate that MHC-mismatched or presentation-incompetent APCs cannot initiate a T CD8+ response in the majority of circumstances, strongly indicating that transfer of peptide-MHC complexes may not be involved in T CD8+ priming.
Our data do not rule out the possibility that SR-A can contribute to cross priming in vivo. Indeed, in vivo targeting of antigen to the SR-A family induced a strong T CD8+ response. 28 Clearly, our data reinforce the previous observation 12 that SR-A is a receptor for molecular chaperones, such as gp96 and CRT. However, the role of peptidechaperone complexes in the transfer of antigen is controversial, as antigenic peptide does not bind to these molecules under physiological conditions. 49, 50 In addition, minimal antigenic peptide or other short-lived molecules are unlikely to be the substrate for cross priming in vivo.
2-4 Nonetheless, immunization with molecular chaperones can elicit T CD8+ , 51 although this response may be the result of an adjuvant effect rather than via direct transfer of antigen. 52 Other scavenger receptors, such as CD36, participate in recognition of pathogen components by toll-like receptors. 53 However, CD36, like SR-A, is not required for cross priming in vivo. 54 Despite a reduction in binding, SR-A )/) DCs readily stimulated antigen-specific T CD8+ . The ability of fucoidin to partially inhibit this process indicates that other receptors, probably scavenger receptors, may play a role in cross priming of peptide-chaperone complexes. Lectinlike oxidized low density lipoprotein receptor 1 (LOX-1) mediates the cross presentation of heat shock protein 70 (hsp70)-peptide complexes, but is not a receptor for gp96. 55 CD91 was first described as a master chaperone receptor. 56, 57 However, the inability of other CD91 ligands to competitively inhibit chaperone binding and subsequent cross presentation indicated that this was not the case, 58, 59 and subsequently the binding activity of SR-A was described. 12 In addition, Schild et al. have described binding of gp96 to TLR2 and TLR4. 60 However, this binding activity may participate in activation of APCs, 60 rather than internalization of antigen, and may be facilitated by the role of gp96 as a 'master chaperone' of TLR folding. 61 The most likely candidate to compensate for a lack of SR-A is scavenger receptor expressed by endothelial cell I (SREC-I), a receptor that can bind and endocytose gp96, CRT and hsp70. 38, 62 Our data currently do not distinguish whether SREC-I exclusively targets peptide-chaperone complexes to the MHC class I cross presentation pathway, or if it fulfils this role in addition to the contribution of SR-A. Inhibition of scavenger receptor binding at 4°with fucoidin reduced but did not ablate the ability of gp96-pulsed BMDCs to elicit T CD8+ responses. Thus, other receptors, such as TLR or other pattern recognition receptors, must be involved in the cross priming response.
Thus, despite strong in vitro evidence to support a role for SR-A in cross presentation, our data indicate that this receptor is not required for cross priming of T CD8+ in vivo. The discrepancies between in vitro and in vivo observations may stem from at least two sources. First, in vitro studies may overestimate the importance of processes such as the transfer of peptide-MHC complexes between cells, a pathway that probably contributes minimally to the induction of antigen-specific T CD8+ during infection in vivo. Secondly, the complex systems studied in vivo probably contain compensatory mechanisms to overcome deficiencies. The redundancy that is incorporated into the cross presentation pathway in vivo prevents the development of strategies by pathogens to subvert presentation via this route. Thus, such redundancy indicates the importance of the cross priming pathway for induction of protective T CD8+ to pathogens and is likely to make therapeutic intervention to block cross presentation in situations such as induction of autoimmune T CD8+ an arduous task.
